| Cat. No. |
Product Name |
Information |
| PC-45507 |
PFI-4
BRPF1 inhibitor
|
PFI-4 is a potent, selective inhibitor of the BRPF1 bromodomain with pIC50 of 7.3. |
| PC-42109 |
BI-7273
BRD9 inhibitor
|
BI-7273 is a potent, selective and cell-permeable BRD9 bromodomain inhibitor with IC50 of 19 nM in Alpha assay. |
| PC-45780 |
PF-CBP1 hydrochloride
CBP/p300 inhibitor
|
PF-CBP1 hydrochloride is a potent, highly selective inhibitor of the CBP and p300 bromodomains with IC50 of 125 nM and 363 nM, respectively. |
| PC-42090 |
GSK6853
BRPF1 inhibitor
|
GSK6853 (GSK-6853) is a potent, highly selective and cell-active BRPF1 bromodomain inhibitor with TR-FRET pIC50 of 8.1. |
| PC-42168 |
CPI-637
CBP/p300 inhibitor
|
A potent and selective, cell-active CBP/EP300 bromodomain inhibitor with CBP BRET EC50 of 0.03 uM. |
| PC-43808 |
I-BET726
BET inhibitor
|
I-BET726 (GSK1324726A) is a potent and selective inhibitor of BET bromodomain with IC50 of 41 nM/31 nM/22 nM for BRD2/BRD3/BRD4 respectively. |
| PC-42230 |
TPOP146
CBP/p300 inhibitor
|
TPOP146 is a potent and selective CBP/p300 bromodomain inhibitor with Kd of 134 nM for CBP bromodomain, displays excellent selectivity over other bromodomains (>30-fold over BRD4 (1)). |
| PC-42029 |
Mivebresib
BET inhibitor
|
Mivebresib (ABBV-075) is a potent and orally available BET bromodomain inhibitor with Ki of 1.0, 12.2, 1.5, and 2.2 nM for BRD2, BRD3, BRD4 and BRDT, respectively. |
| PC-24237 |
KB-0118
BET bromodomain
|
KB-0118 is a selective BET bromodomain inhibitor with Kd of 36.7 uM for BRD2 BD1 and 47.4 uM for BRD4 BD1, shows immunomodulatory effects in inflammatory bowel disease (IBD). |
| PC-23888 |
LC-CE-7
CECR2 inhibitor
|
LC-CE-7 is a potent, sepecific and allosteric covalent CECR2 inhibitor with IC50 of 462 nM and Ki of 32.5 nM, exhibits covalent binding to Cys494 and allosteric regulation of the Kac pocket. |
| PC-23763 |
IEM930
GAS41/YEATS4 inhibitor
|
IEM930 is a small molecule inhibitor targeting the GAS41 YEATS domain (YEATS4)) with ITC binding Kd of 32.6 uM, inhibits GAS41/ITGA4-mediated PI3K/Akt/mTOR signaling pathway in glioma cells. |
| PC-23754 |
CZL-046
p300 bromodomain inhibitor
|
CZL-046 is a potent, selective, and orally active p300 bromodomain inhibitor with IC50 of 3.3 nM, exhibits antiproliferative activity in the multiple myeloma (MM) cell line (OPM-2, IC50=51.5 nM). |
